Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity‑Modulated Radiation Therapy
In patients with anal squamous cell carcinoma treated with definitive‑intent intensity‑modulated radiation therapy, locoregional control rates were high and isolated nodal failures were rare, yet locoregional recurrence portended poor survival and salvage therapy yielded improved long‑term outcomes.
Purpose: Patterns of failure and salvage therapy options for patients with anal squamous cell carcinoma (ASCC) who recur after definitive-intent intensity‑modulated radiation therapy (IMRT) with concurrent chemotherapy are not well described. Methods and Materials: We identified consecutive patients with ASCC treated with definitive-intent IMRT between July 2005 and December 2019. Relevant patient and tumor parameters, disease outcomes (locoregional failure [LRF], distant failure, progression‑free survival, colostomy‑free survival, and overall survival [OS]), patterns of failure, and salvage therapies were collected. Failures were analyzed using competing risk methods, whereas survival endpoints were estimated using the Kaplan‑Meier method. Univariate and multivariate analyses were performed. Landmark analyses were conducted by considering whether patients had LRF within 12 months of completing IMRT. Results: A total of 375 patients were identified with a median follow‑up of 6 years. Stage breakdown was 15%, 23%, and 62% for the American Joint Committee on Cancer stages 0 to I, II, and III, respectively. Six‑year rates of LRF, distant failure, progression‑free survival, colostomy‑free survival, and OS were 12%, 13%, 73%, 76%, and 80%, respectively. Disease recurred in 74 patients. Among the 45 patients with LRF, 39 (87%) failed within the anorectum, with 25 anal canal, 6 anal margin, and 8 rectal recurrences. Only 4 (9%) patients had isolated nodal failure. Patients experiencing LRF had worse 6‑year OS than patients without LRF (44% vs 86%, P < .0001). Approximately 30% of patients who underwent salvage therapy were alive to 10 years after recurrence, compared with none of the patients who were managed with chemotherapy alone or the best supportive care. Conclusions: This large ASCC cohort managed with definitive‑intent IMRT demonstrated excellent rates of locoregional control and survival. Isolated regional nodal failures were uncommon, whereas the majority of LRFs occurred within the anorectum, despite dose escalation by tumor stage. We observed poor outcomes for patients experiencing locoregional disease recurrence, even after aggressive salvage treatment.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Advancements in Immunotherapy for Anal Cancer Treatment
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden
- Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline